

CIN: L24222TN1992PLC022994

February 13, 2015

**The Manager
Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor, Plot No: C/1
G - Block, Bandra - Kurla Complex
Bandra (East), Mumbai – 400 051**

Dear Sir/Madam,

Sub: Unaudited Financial Results for the Quarter ended 31st December, 2014

In accordance with the Clause 41 of the listing agreement, we are enclosing the following

- ❖ Copy of the Unaudited Financial Results of the Company for the quarter ended December 31, 2014 along with the press release in this respect.
- ❖ Copy of the limited review report on the aforesaid Unaudited Financial Results as issued by the Statutory Auditors of the Company.

The above Unaudited Financial Results and the limited review report have been taken on record by the Board of Directors at their meeting held on February 13, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,



**L Chandrasekar
Executive V P – Finance & Secretary.**

Encl.: a/a



UNAUDITED FINANCIAL RESULTS FOR QUARTER / FIFTEEN MONTHS ENDED DECEMBER 31, 2014

**Orchid Chemicals
& Pharmaceuticals Limited**

Sl. No.	Particulars	Rs. lakhs				
		Three months ended			Fifteen Months ended	18 months ended
		31-Dec-2014 (Unaudited)	30-Sep-2014 (Unaudited)	31-Dec-2013 (Unaudited)	31-Dec-2014 (Unaudited)	30-Sep-2013 (Audited)
1	Net Sales / Income from Operations (Net of Excise Duty)	15,902.21	17,480.91	36,881.97	1,42,973.28	1,84,950.03
2	Other Operating Income	551.31	17.99	278.08	1,921.50	9,684.05
3	Total Operating Income (1+2)	16,453.52	17,498.90	37,160.05	1,44,894.78	1,94,634.08
4	Expenditure					
	a) Cost of materials consumed	12,592.96	8,915.58	15,763.18	62,874.78	82,246.39
	b) Purchases of stock-in-trade	11.65	27.44	120.00	272.70	5,099.37
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,642.23)	(2,785.48)	(1,290.49)	(672.63)	8,481.03
	d) Employees Cost	2,134.75	4,164.31	3,294.09	16,397.25	23,705.13
	e) Depreciation / Amortisation	4,430.18	4,548.94	5,740.73	26,110.03	24,386.87
	f) Other Expenditure	4,645.65	8,387.65	8,324.09	38,578.95	58,141.83
	g) Total	18,172.96	23,258.44	31,951.60	1,43,561.08	2,02,060.62
5	Profit / (Loss) from Operations before Other Income, Interest, Exceptional Item (3-4)	(1,719.44)	(5,759.54)	5,208.45	1,333.70	(7,426.54)
6	Other Income	1.01	75.37	0.16	77.70	1.31
7	Profit / (Loss) before Interest & Exceptional Item (5+6)	(1,718.43)	(5,684.17)	5,208.61	1,411.40	(7,425.23)
8	Finance cost	7,456.44	6,585.54	9,555.73	43,248.27	52,038.06
9	Profit/(loss) after interest but before Exceptional Item (7-8)	(9,174.87)	(12,269.71)	(4,347.18)	(41,836.87)	(59,463.29)
10	Exceptional Item - Gain/(Loss)	(5,230.19)	(1,657.24)	(1,043.06)	(5,632.84)	5,111.08
11	Profit/(Loss) before Tax (9+10) from Ordinary activities	(14,405.06)	(13,926.95)	(5,390.24)	(47,469.71)	(54,352.21)
12	Tax expenses					
	- Current Tax & Deferred Tax	(2,395.63)	(9,240.72)	-	(11,290.20)	(1,329.56)
13	Profit/(Loss) after Tax (11-12) from Ordinary activities	(12,009.43)	(4,686.23)	(5,390.24)	(36,179.51)	(53,022.65)
14	Extra-ordinary Items - Gain/(Loss) (Net of Tax of Rs.9340.72 Lakhs)	-	31,880.46	-	31,880.46	-
15	Net Profit/(Loss) for the period (13+14)	(12,009.43)	27,194.23	(5,390.24)	(4,299.04)	(53,022.65)
16	Paid-up Equity Share Capital (Face value of Rs.10/- each)	8,526.19	7,045.21	7,045.21	8,526.19	7,045.21
17	Reserves excluding Revaluation Reserves	-	-	-	-	41,771.33
18	Earnings per share (EPS) before extra-ordinary item					
	- Basic Rs.*	(14.09)	(6.65)	(7.65)	(42.43)	(75.26)
	- Diluted Rs.*	(14.09)	(6.65)	(7.65)	(42.43)	(75.26)
19	Earnings per share (EPS) after extra-ordinary item					
	- Basic Rs.*	(14.09)	38.60	(7.65)	(5.04)	(75.26)
	- Diluted Rs.*	(14.09)	30.78	(7.65)	(5.04)	(75.26)

* EPS for the period (not annualised)

Sl.No	Particulars	As at 31-Dec-2014	As at 30-Sep-2014	As at 31-Dec-2013	As at 31-Dec-2014	As at 30-Sep-2013
A	PARTICULARS OF SHAREHOLDING					
1	Public Shareholding					
	- Number of equity shares	4,77,11,295	4,77,11,295	4,77,11,295	4,77,11,295	4,77,11,295
	- Percentage of Shareholding	55.96	67.72	67.72	55.96	67.72
2	Promoters and Promoter group shareholding					
	a. Pledged / Encumbered					
	- Number of shares	3,54,33,453	1,93,23,652	1,72,76,400	3,54,33,453	1,89,41,608
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	94.36	84.97	75.97	94.36	83.29
	- Percentage of shares (as a % of the total share capital of the company)	41.56	27.43	24.52	41.56	26.89
	b. Non - Encumbered					
	- Number of shares	21,17,129	34,17,129	54,64,381	21,17,129	37,99,173
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	5.64	15.03	24.03	5.64	16.71
	- Percentage of shares (as a % of the total share capital of the company)	2.48	4.85	7.76	2.48	5.39



Handwritten signature



Orchid Chemicals
& Pharmaceuticals Limited

UNAUDITED FINANCIAL RESULTS FOR QUARTER / FIFTEEN MONTHS ENDED DECEMBER 31, 2014

Rs. lakhs

PARTICULARS	
B	INVESTOR COMPLAINTS
Pending at the beginning of the quarter	- NIL -
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	- NIL -
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2015 and have been subjected to limited review by the statutory auditors.
2	The Company is operating in single segment (i.e) "Pharmaceuticals".
3	The Company's Corporate Debt Restructuring package, approved by the CDR Empowered Group vide its Letter of Approval Dt.10/03/2014, has been implemented in July 2014.
4	During the above period, 1,48,09,801 equity shares of Rs.10/- each at a premium of Rs.39.79/- per share were allotted to the promoters in accordance with SEBI guidelines against the promoter contribution brought in by the promoters as per the conditions of CDR. These shares would be pledged in favour of the Lenders as per conditions of CDR Package upon receipt of the listing /trading approval from the Stock Exchanges where the shares are listed.
5	Exceptional items for three months ended December 31, 2014 represents amortisation of exchange loss on restatement of Foreign currency loans amounting to Rs.1,230.18 Lakhs and Provision for contingencies relating to transferred business amounting to Rs.4000 Lakhs.
6	The Company had exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated March 31, 2009. The Ministry of Corporate affairs vide notification dated 29/12/2011 has extended the amortisation of gains or losses arising on reporting of foreign currency monetary items over the balance period of such long term asset/liability. Accordingly exchange loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortised in the financial statements as at December 31, 2014 on account of exercising the above option is Rs.12,502.83 Lakhs.
7	The Company has extended the Financial year to March 31, 2015.
8	The auditors have observed matters relating to recovery of certain advances paid to suppliers, non-provision of diminution in value of investments in a foreign R&D subsidiary and reconciliation of all bank accounts by the Company after CDR completion. The Corporate Debt Restructuring scheme already approved has been implemented in July 2014. Due to financial constraints, the Company was not able to take delivery of materials/capital goods and the company is confident that with the CDR implementation, the company would be able to take delivery of these materials in due course. As far as the diminution in value of investments is concerned, the Company is confident that the value of molecules held by the foreign subsidiary will be more than the investment. With the implementation of the CDR scheme in July 2014, the interest liability / credits to the extent confirmed has been accounted for. However final confirmation from few Banks are awaited and the management is confident that there will be no impact on the financials on account of the matters referred to in the audit report. In case of certain stocks taken over under the Business Transfer, the amounts are recoverable from the buyer for which agreements are being entered into..
9	Previous period figures have been regrouped wherever necessary.
<p>Place : Chennai Date : February 13, 2015</p> <p style="text-align: right;">For and on behalf of the Board K.N. Venkatasubramanian Chairman</p>	



BSE: 524372 NSE: ORCHIDCHEM Bloomberg: OCP@IN Reuters: ORCD.BO

Q5 FY15 Earnings

Chennai, India - February 13, 2015

Orchid Pharma registers turnover of Rs 164.52 crore in Q5 FY15

Financial highlights for Quarter ended December 31, 2014 (Q5 FY15) - Standalone

Revenue of Rs 164.54 crore (US\$ 26.1 million) in the quarter ended December 31, 2014 (Q5 FY14) as compared to Rs 371.60 crore (US\$ 58.9 million) registered during the corresponding quarter ended December 31, 2013.

*** 1 US\$ = Rs 63.03**

The company has extended its current financial and accounting year by six months to *March 31, 2015. This is to fall in line with the new Companies Act requirement.*

The Company has obtained approval from "LAGeSo Berlin", an European Regulatory Authority for Good Manufacturing Practices (GMP) in November 2014 for its Alathur API manufacturing facility.

From the Managing Director

"With the availability of working capital in place, the Company is currently stabilizing itself in the market through increased production and sales level. We are confident that the Company would reach optimum production/sales levels from the first quarter of the financial year 2015-16 and the efforts of the Company for achieving this are on track", said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.


About Orchid Pharma

Orchid Chemicals & Pharmaceuticals Ltd. is a leading pharmaceutical company headquartered in Chennai, India involved in the development; manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. With exports spanning more than 75 countries, Orchid is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the Top 5-cephalosporin producers in the world. Orchid's world-class manufacturing infrastructure including USFDA and UK MHRA approved API and dosage form facilities are located at Chennai. Orchid has dedicated state-of-the-art GLP compliant R&D centres for API research, drug

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Orchid Pharma Q5 FY15 earnings

13/02/15





discovery and pharmaceutical research at Chennai. Orchid has ISO 14001 and OHSAS 18001 certifications. Orchid is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India.

Additional information is available at the company's website at www.orchidpharma.com

For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.

A handwritten signature in black ink, appearing to read 'S. Karthikeyan', is written over the printed name.

Executive Vice President - Finance & Secretary

‘Orchid Towers’, #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

SNB ASSOCIATES

CHARTERED ACCOUNTANTS

12, 3rd Floor, Gemini Parsn Complex, 121, Mount Road, Chennai - 600 006 Phone 28224382

AUDITORS' REPORT

**TO THE BOARD OF DIRECTORS OF
ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED
ON LIMITED REVIEW OF UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND PERIOD ENDED DECEMBER 31, 2014**

We have reviewed the accompanying statement of unaudited financial results of **ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED** ("the Company") for the quarter and period ended 31st December 2014 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding", which have been traced from disclosures, made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

- I. The Company has given advances amounting to Rs. 606.72 Crores to various parties and are outstanding as on December 31, 2014. The Company has not received major materials/ capital goods from the time these specific advances were given. As per information and explanation given, the Company is not able to take delivery of materials due to financial constraints. We are not able to express any opinion on the recoverability of these amounts.**
- II. The Company has investments of Rs. 94.82 Crores and loans of Rs. 34.49 Crores in a wholly owned subsidiary Bexel Pharmaceuticals Inc. The subsidiary has not been spending any money on the research on the molecule during the current period as no financial support is given by the parent Company and the parent Company has not allocated any funds for the future development. In view of the above, it is necessary to impair the value of this investment as no information is available with the Company regarding the value that can be recovered from the sale of rights over the molecule possessed by the Subsidiary.**



Mumbai : A-503, Sagar Tech Plaza, Near Saki Naka Signal Andheri Kurla Road, Andheri (East) Mumbai - 400 072.
Phone : 2852 7551, 6552 9767, 6559 3571

Bangalore : W-304, Sunrise Chambers, 22, Ulsoor Road, Bangalore - 560 042. Phone : 2559 7980, 2558 2043

- III. The Company debt restructuring process has been approved. The Company as at 31st December 2014 has not received final confirmation of balances from some of the banks/ institution relating to the loan and interest funded. The entries have been passed based on the information available with the company and the interest so accounted are subject to effect of final reconciliation and confirmation of all the banks.**
- IV. The Company has accounted for stocks lying at Aurangabad amounting to Rs. 17.02 Crores which is recoverable from future billing. The Company is yet to enter into agreement for the above arrangement.**

Based on our review conducted as above, subject to the previous paragraphs(I to IV) above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is disclosed, or that it contains any material misstatements .

For SNB ASSOCIATES
Chartered Accountants
Firm Registration No. 015682N



T.K Shanmugam
Partner
M.No: 016195



Date: February 13, 2015
Place: Chennai